The healthcare industry in the United States is in dire need of reform, and the culprit is the so-called 'Big Medicine' conglomerates. These entities, including pharmacy benefit managers (PBMs), insurance companies, and drug distributors, have been driving up healthcare costs and stifling competition, ultimately harming both patients and providers. The situation is dire, and it's high time we address the root causes of these issues.
One of the key players in this saga is the PBMs. These middlemen between insurers, drug manufacturers, and pharmacies have been accused of reducing drug costs, but the evidence suggests otherwise. The 'big three' PBMs, CVS Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum Rx, control a staggering 80% of US prescriptions and are vertically integrated with major insurance and pharmacy companies. This integration allows them to leverage their market power to drive up drug costs and push independent pharmacies out of business. For instance, a 2025 report by the Federal Trade Commission found that these PBMs paid their affiliated pharmacies up to 7,736% more than unaffiliated competitors.
But PBMs aren't the only culprits. Drug wholesalers, such as McKesson, Cencora, and Cardinal Health, control 96% of US drug distribution and are also vertically integrated with medical providers. This arrangement creates conflicts of interest, as seen in the case of Cencora, which agreed to pay $1 million to resolve allegations of paying kickbacks to healthcare providers. These wholesalers can dictate which drugs patients receive, putting their profit margins ahead of doctors' clinical judgment.
The pharmaceutical industry, or Big Pharma, has also been accused of abusing patents to keep drug costs high and block competition from more affordable generics. However, this doesn't absolve the other players in the Big Medicine ecosystem. In fact, the PBMs have been quick to point the finger at Big Pharma, launching a seven-figure advertising campaign to blame them for high drug costs. But this is a distraction from the real issue - the power dynamics within the healthcare industry.
The situation is further complicated by the fact that PBM reform efforts have stalled for years due to fierce opposition from industry groups. Elon Musk even played a role in tanking a bipartisan government funding bill that included PBM reforms. However, lawmakers have finally managed to get some reforms into a spending bill, banning PBMs from pocketing manufacturer rebates and excluding independent pharmacies from their networks in Medicare Part D. But these reforms only scratch the surface.
To truly address the issue, we need to break up the Big Medicine companies. The Break Up Big Medicine Act, introduced by Senators Elizabeth Warren and Josh Hawley, would prohibit insurers, PBMs, and wholesalers from owning or controlling healthcare providers. This bill would effectively break up all six of the Big Medicine companies, aiming to lower healthcare costs and promote competition. Research shows that such a ban would reduce drug prices by more than 7%, and public support for this kind of legislation is growing.
The parallels between the Glass-Steagall Act, which separated commercial and investment banks during the Great Depression, and the Break Up Big Medicine Act are striking. Just as the Glass-Steagall Act aimed to prevent systemic risks, the Break Up Big Medicine Act seeks to prevent the catastrophic threat that Big Medicine poses to the US healthcare system. While it won't heal all the system's problems, it will be a significant step towards recovery. It's time to take a stand and break up the Big Medicine conglomerates before they continue to harm patients, providers, and the economy as a whole.
